Morphological Changes in Leukemic Lymphoblasts and Normal Lymphocytes Treated with Deoxyadenosine Plus Deoxycoformycin

References

• Giblett E R, Anderson J E, Cohen F, et al. Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 1972; 2: 1067–1069
   PubMed Web of Science ®Google Scholar
• Meuwissen H J, Pollara B, Pickering R J. Combined immunodeficiency disease associated with adenosine deficiency. J Pediatr 1975; 86: 169–181
   PubMed Web of Science ®Google Scholar
• Roller C A, Mitchell B S, Grever M R, et al. Treatment of acute lymphoblastic leukemia with 2′-deoxycoformycin, clinical and biochemical consequences of adenosine deaminase inhibition. Cancer Treat Rep 1979; 63: 1949–1952
   PubMedGoogle Scholar
• Yu A L, Kung F H, Bakay B, et al. In vitro and in vivo effect of deoxycoformycin in human T cell leukemia. Adv Exp Med Biol 1980; 122b: 373–379
   Google Scholar
• Prentice H G, Smyth J F, Ganeshaguru K, et al. Remission induction with adenosine-deaminase inhibitor 2′-deoxycoformycin in Thy-lymphoblastic leukemia. Lancet 1980; 2: 170–172
   PubMed Web of Science ®Google Scholar
• Carson D A, Kaye J, Seegmifler J E. Differential sensitivity of human leukemic T-cell lines and B-cell lines to growth inhibition by deoxyadenosine. J Immunol 1978; 121: 1726–1731
   PubMed Web of Science ®Google Scholar
• Carson D A, Kaye J, Matsumoto S, et al. Biochemical basis for the toxicity of deoxyribonucleosides toward malignant human T cell lines. Proc Natl Acad Sci USA 1979; 76: 2430–2433
   PubMed Web of Science ®Google Scholar
• Mitchell B S, Mejias E, Daddona P E, et al. Purinogenic immunodeficiency diseases: Selective toxicity of deoxyribonucleosides for T-cells. Proc Natl Acad Sci USA 1978; 75: 5011–5014
   PubMed Web of Science ®Google Scholar
• Carson D A, Wasson D B, Lakow E, et al. Possible metabolic basis for the different immunodeficient states associated with genetic deficiencies of adenosine deaminase and purine nucleoside phosphorylase. Proc Natl Acad Sci USA 1982; 79: 3848–3852
   PubMed Web of Science ®Google Scholar
• Kefford R D, Fox R M. Purine deoxynucleoside toxicity in non-dividing human lymphoid cells. Cancer Res 1982; 42: 324–330
   PubMed Web of Science ®Google Scholar
• Cohen A, Hirschhorn R, Horowitz S A, et al. Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency. Proc Natl Acad Sci USA 1978; 75: 472–476
   PubMed Web of Science ®Google Scholar
• Coleman M S, Donofrio I, Hutton J J, et al. Identification and quantitation of adenine deoxynucleotides in erythrocytes of a patient with adenosine deaminase deficiency and severe combined immunodeficiency. J Biol Chem 1978; 253: 1619–1626
   PubMed Web of Science ®Google Scholar
• Henderson J F, Scott F W, Lowe J K. Toxicity of naturally occurring purine deoxyribonucleosides. Pharmacol Ther 1980; 8: 573–604
   PubMed Web of Science ®Google Scholar
• Siaw M FE, Mitchell B S, Roller C A, et al. ATP depletion as a consequence of adenosine deaminase inhibition in man. Proc Natl Acad Sci USA 1980; 77: 6157–6161
   PubMed Web of Science ®Google Scholar
• Hershneld M S. Apparent suicide inactivation of human lymphoblast S-adenosylhomocysteine hydrolase by 2′-deoxyadenosine and adenine arabinoside. J Biol Chem 1979; 254: 22–25
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Yu A L. Inhibition of RNA synthesis by deoxyadenosine plus deoxycoformycin in resting lymphocytes. J Immunol 1983; 131: 2762–2766
   PubMed Web of Science ®Google Scholar
• Gills S, Watson J. Biochemical and biological characterization of lymphocyte regulatory molecules, V. Identification of an interleukin 2- producing human leukemia T cell line. J Exp. Med 1980; 152: 1709–1719
   Web of Science ®Google Scholar
• Hiraki S, Miyoshi I, Rubonishi I, et al. Human leukemic ‘null’ cell line (NALL-1). Cancer 1977; 40: 2131–2135
   PubMed Web of Science ®Google Scholar
• Minowada J, Tsubota T, Greaves M F, et al. Non T, Non B human leukemia cell line (NALM-1): Establishment of the cell line and presence of leukemia-associated antigens. J Natl Cancer Inst 1977; 59: 83–87
   PubMed Web of Science ®Google Scholar
• Minowada J. Markers of human leukemia-lymphoma cell lines reflect haematopoietic cell differentiation in human lymphocyte differentiation: its application to cancer. INSERM Symposium, B Serrou, C Rosenfeld. Elsevier-North Holland, Amsterdam 1978; vol. 8: 377–344
   Google Scholar
• Bakay B. A novel method of sample transport and its application for continuous detection of radioactivity in the effluent of the high speed amino acid analyser. Anal Biochem 1975; 63: 87–98
   PubMed Web of Science ®Google Scholar
• Matsumoto S S, Yu A L, Bleeker L C, et al. Biochemical correlates of the differential sensitivity of subtypes of human leukemia to deoxyadenosine and deoxycoformycin. Blood 1982; 60: 1096–1102
   PubMed Web of Science ®Google Scholar
• Karnovsky M J. A formaldehyde-glutaraldehyde fixative of high osmolality for use in electron microscopy (abstr.). J Cell Biol 1965; 27: 137–138a
   Web of Science ®Google Scholar
• Reynolds E S. The use of lead citrate at high pH as an electron opaque stain in electron microscopy. J Cell Biol 1963; 17: 208–212
   PubMed Web of Science ®Google Scholar
• Carson D A, Kaye J, Wason D B. The potential importance of soluble deoxynucleotidase activity in mediating deoxyadenosine toxicity in human lymphoblasts. J Immunol 1981; 126: 348–352
   PubMed Web of Science ®Google Scholar
• Fox R M, Tripp E H, Piddington S K. Sensitivity of leukemic human null lymphocytes to deoxynucleosides. Cancer Res 1980; 40: 3383–3386
   PubMed Web of Science ®Google Scholar
• Yu A L, Bakay B, Kung F H, et al. Effects of 2′-deoxycofor-mycin on the metabolism of purines and the survival of malignant cells in a patient with T-cell leukemia. Cancer Res 1981; 41: 2677–2682
   PubMed Web of Science ®Google Scholar
• Lefevre P G, Marshall J K. The attachment of phloretin and analogues to human erythrocytes in connection with inhibition of sugar transport. J Biol Chem 1959; 234: 3022–3026
   PubMed Web of Science ®Google Scholar
• Mizel S B, Wilson L. Inhibition of the transport of several hexoses in mammalian cells by cytochalasin B. J Biol Chem 1972; 247: 4102–4105
   PubMed Web of Science ®Google Scholar
• Tannebaum J, Tannenbaum S W, Godman G C. The binding sites of cytochalasin D. II. Their relationship to hexose transport and to cytochalasin B. J Cell Physiol 1977; 91: 239–248
   PubMed Web of Science ®Google Scholar
• Kefford R F, Helmer M A, Fox F M. S-adenosylhomocysteine hydrolase inhibition in deoxyadenosine-treated human T-lymphoblasts and resting peripheral blood lymphocytes. Cancer Res 1982; 42: 3822–3827
   PubMed Web of Science ®Google Scholar
• Policard P A, Bessis M. Etudes sur l'element vivant en pathologie cellulaire. L'emploi de la microcinematographie en contraste de phase. Rev D'Hemat 1953; 8: 57–70
   PubMedGoogle Scholar
• Poste G. Enucleation of mammalian cells by cytochalasin B. I. Characterization of anucleate cells. Cell Res 1972; 73: 273–286
   Web of Science ®Google Scholar
• Flanagan M D, Lin S. Cytochalasins block actin filament elongation by binding to high affinity sites associated with F-actin. J Biol Chem 1980; 255: 835–838
   PubMed Web of Science ®Google Scholar
• Hartwig H H, Stossel T P. Cytochalasin B and the structure of actin gels. J Mol Biol 1979; 134: 539–553
   PubMed Web of Science ®Google Scholar
• MacLean-Fletcher S, Pollard T D. Mechanism of action of cytochalasin B on actin. Cell 1980; 20: 329–341
   PubMed Web of Science ®Google Scholar